Conference Call & Webcast
Thursday, August 13, 2015 at 8:00 a.m. EST/5:00 a.m. PST
Domestic: 888-329-8893
Israel: 1 80 924 5906
International: 719-325-2354
Conference ID: 5122591
Webcast: http://public.viavid.com/player/index.php?id=115681
Replay will be available through August 27, 2015
Domestic: 877-870-5176
International: 858-384-5517
Conference ID: 5122591
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn has been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States. For more information, visit the company's website at www.brainstorm-cell.com.
Media - Tony Fiorino, MD, PhD, Chief Executive Officer, BrainStorm Cell Therapeutics Inc., 201-488-0460, info@brainstorm-cell.com; or Investors - Michael Wood, LifeSci Advisors, LLC, 646-597-6983, mwood@lifesciadvisors.com